In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Quantification of left ventricular trabeculations using fractal analysis in children

Session Poster session 1

Speaker Sylvia Krupickova

Congress : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance: Myocardium
  • Session type : Poster Session
  • FP Number : P180

Authors : S Krupickova (London,GB), S Hatipoglu (London,GB), G Di Salvo (London,GB), I Voges (London,GB), S Foldvari (London,GB), CH Eichhorn (London,GB), S Chivers (London,GB), SK Prasad (London,GB), PEF Daubeney (London,GB)

Authors:
S Krupickova1 , S Hatipoglu2 , G Di Salvo1 , I Voges1 , S Foldvari1 , CH Eichhorn1 , S Chivers1 , SK Prasad2 , PEF Daubeney1 , 1Royal Brompton Hospital, Paediatric Cardiology - London - United Kingdom of Great Britain & Northern Ireland , 2Royal Brompton Hospital, CMR department - London - United Kingdom of Great Britain & Northern Ireland ,

On behalf: NA

Citation:
European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii139

Introduction: There are great difficulties in the current definitions of left ventricular non-compaction (LVNC). Fractal analysis as a cardiac magnetic resonance (CMR) diagnostic measure has been studied in adults and has been shown to be a useful quantitative measure of trabeculation with high reproducibility and accuracy for LVNC diagnosis when compared to current CMR methods (Petersen and Jacquier).

Purpose: The aim of this study is to investigate the utility of fractal analysis in establishing the diagnosis of LVNC in paediatric population.

Methods: Altogether 84 subjects were analysed: 1) 28 patients with LVNC as defined by Petersen on CMR (ie non-compacted to compacted layer (NC/C) ratio>2.3); 2) 28 patients referred by clinicians for CMR with hypertrabeculation and found not to qualify as LVNC by Petersen (ie NC/C < 2.3); 3) 28 subjects (controls) with a normal scan. All 3 groups were age and gender matched. 

The fractal scores for each group were presented for 3 sites in the left ventricle (LV): basal, mid and apical layer, as well as global LV score (mean) and maximal score. Statistical comparison of the fractal scores between the 3 groups has been performed. 

Results: Global fractal dimension (FD) was higher in the LVNC group than in the hypertrabeculated group (1.35±0.05 vs 1.25±0.03, p<0.001) and higher in hypertrabeculated group than in controls (1.25±0.03 vs 1.16±0.04, p<0.01). Maximal FD was the highest in the LVNC group and higher in hypertrabeculated group when compared to controls (1.48±0.04 vs 1.35±0.03, p<0.01; 1.35±0.03 vs 1.26 ± 0.04, p<0.01). The highest mean FD was in the apical part in LVNC group (1.43±0.06) whereas it was 1.30±0.03 in the mid ventricle in hypertrabeculated and 1.23±0.04 in the healthy group.

Conclusion: There are multiple diagnostic difficulties in establishing LVNC diagnosis in children. We have shown that it is technically feasible to perform fractal analysis in children using CMR. Fractal scoring accurately distinguishes between LVNC, LV hypertrabeculation and healthy controls. This may help with the diagnostic limitations of the currently used diagnostic CMR methods.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are